NDATOPICALJELLY
Approved
Mar 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
XYLOCAINE (lidocaine hydrochloride) by AstraZeneca is 12. First approved in 1953.
Drug data last refreshed 37m ago · AI intelligence enriched 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XYLOCAINE (lidocaine hydrochloride) is a topical local anesthetic jelly approved in 1953 that stabilizes neuronal membranes to inhibit ionic fluxes required for nerve impulse initiation and conduction. It is used for topical anesthesia in procedures requiring localized pain relief, with rapid hepatic metabolism and a 1.5-2 hour elimination half-life. The drug crosses blood-brain and placental barriers via passive diffusion and is primarily excreted as metabolites through the kidneys.
$0.005BPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D utilization, signaling transition to mature/generic phase and potential right-sizing of commercial team.
Mechanism of Action
12.1 Mechanism of Action Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. 12.2 Pharmacodynamics Excessive blood levels may cause changes in cardiac output, total…
Worked on XYLOCAINE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.